Clinical trial
To Determine if Olanzapine is More Cost Effective Than Haloperidol for the…
NCT00007774 · US Department of Veterans Affairs, U.S. Fed · Completed
Key facts
| NCT number | NCT00007774 |
|---|---|
| Title | To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia |
| Official title | CSP #451 - The Clinical and Economic Impact of Olanzapine in the Treatment of Schizophrenia |
| Lead sponsor | US Department of Veterans Affairs, U.S. Fed |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizoaffective Disorder, Schizophrenia |
| Intervention type | Drug |
| Interventions | Haloperidol, Olanzapine |
| Enrollment | 600 |
| Start date | Mar 1, 1998 |
| Primary completion | Jun 1, 2001 |
| First posted | Jan 1, 2001 |
| Last update posted | Feb 4, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: